New Perspective Focuses on New Challenges of breast cancer Treatment in China, Helps Scientific Diagnosis and Treatment Develop in High Quality in Shanghai | Treatment | breast cancer

Recently, the "13th New Perspective breast cancer Summit Forum" was held in Beijing, Shanghai and Guangzhou in the form of online conference. At the meeting, experts in the field of breast cancer prevention and control jointly focused on the new challenges of treatment for domestic breast cancer patients, especially HR+breast cancer patients, with a new perspective, exchanged views on how to further reduce the recurrence risk and improve the net benefits of treatment, accurately divide the population to optimize treatment plans, strengthen standardized treatment and quality control of breast cancer and other topics, and jointly looked forward to the new pattern of breast cancer whole process management.

Academician of the Chinese Academy of Engineering, Academician Xu Binghe of the National New Drug Clinical Research Center, Professor Shao Zhimin of Fudan University Cancer Hospital, Professor Wu Jiong of Fudan University Cancer Hospital, Professor Jin Feng of the First Affiliated Hospital of China Medical University, Professor Wang Yongsheng of Shandong Cancer Hospital, Tianjin Medical University Cancer Hospital Professor Zhang Jin, Professor Hu Xichun of Fudan University Cancer Hospital and other hundreds of breast cancer experts from across the country attended the conference.

According to GLOBOCAN 2020 data, female breast cancer surpassed lung cancer as the most common cancer in the world for the first time. In 2020, there were more than 2.26 million new cases of breast cancer in the world. The latest data from the National Cancer Center shows that breast cancer is the largest cancer threatening the health of Chinese women, and the incidence rate is increasing year by year. At the same time, with the establishment of molecular typing diagnosis and treatment mode of breast cancer and the accelerated iteration of treatment drugs, the diagnosis and treatment level of breast cancer has improved year by year, and the overall 5-year survival rate has reached 90%.

Academician of the CAE Member and Academician Xu Binghe of the National Center for Clinical Research of New Drugs pointed out that "the effect of breast cancer prevention and control is of great significance to the overall cancer prevention and control work in China. With the support of relevant government departments, breast cancer screening work continues to advance, comprehensive treatment continues to progress, and new technologies, new therapies and new drugs accelerate the development and implementation, which has contributed to the significant improvement of breast cancer diagnosis and treatment in recent years, bringing breast cancer prevention and treatment into the era of" chronic disease ". The new prevention and control stage requires us to focus on new challenges with a 'new perspective', explore new opportunities with a scientific spirit, and on the basis of standardized diagnosis and treatment, individualized and precise treatment are given according to the molecular classification of breast cancer. The treatment of patients is better, and the" two guarantees "health management strategy is used throughout the whole process of treatment and rehabilitation of patients, so as to improve the long-term life and quality of life of more patients. At the same time, the value of scientific innovation is transformed into the treatment benefits of more grass-roots patients through the expansion and sinking of high-quality medical resources“

In the context of breast cancer's overall "slow disease" management, patients have more treatment needs to be met. Especially for up to 70% of domestic HR+breast cancer patients, taking patients receiving endocrine therapy as an example, for 5-10 years of drug treatment, patients may face treatment related or concomitant adverse reactions caused by diseases, such as cardiovascular problems, osteoporosis, dyslipidemia, mental problems, etc., which require standardized diagnosis and treatment, single disease genetic control, and the "interdisciplinary" management model to achieve the goal of actively managing health level while curing diseases for patients.

Professor Shao Zhimin, Cancer Hospital Affiliated to Fudan University, said: "In recent years, significant progress has been made in the exploration of personalized treatment for HR+breast cancer patients. The concept of 'net benefit' has further promoted disease treatment to define clinical value from the perspective of patients, and focus on influential factors other than efficacy, so as to develop more optimized treatment plans for patients. In this process, patients further become the main body of treatment, and also requires us to continue to explore from multiple dimensions, such as clinical research, treatment plan formulation, patient management, standardized diagnosis and treatment system, and quality control implementation, so as to open a new chapter in HR+breast cancer treatment. We look forward to achieving a longer survival period for more HR+breast cancer patients under the premise of standardized treatment in the future. Better quality of life, return to family and society“

Compared with HR+early breast cancer treatment, more attention is paid to the balance of efficacy and toxicity, while the treatment of late breast cancer aims to achieve a longer survival period and better quality of life, and gradually moves closer to "chronic disease management".

Professor Wang Kun, Cancer Hospital of Guangdong Provincial People's Hospital, pointed out: "Since the first CDK4/6 inhibitor was launched in China in 2018, we have accumulated nearly five years of clinical medication experience, and the recent real world research at home and abroad has further promoted the real world data of Chinese population, providing strong evidence-based medical support for the widespread application of CDK4/6 inhibitor combined with endocrine therapy in HR+/HER2 advanced breast cancer patients. In the future, we hope to find out the dominant population by screening biological targets, and look forward to further HR+breast cancer treatment."

After 12 years, the New Perspective breast cancer Summit Forum has created a multi-dimensional, all-round and high-quality professional exchange platform for Chinese experts in the field of breast cancer, leading the field of breast cancer to constantly open new chapters. From the practice of the "all-round and full cycle" health management concept, continuing to promote multi-disciplinary diagnosis and treatment of tumors, to building a national breast cancer standardized diagnosis and treatment and quality control system, Pfizer has continued to help China's breast cancer diagnosis and treatment high-quality development with the help of the new perspective platform and experts and scholars.